GlassScriptPhysician profile
Mark A Marinella
NPI 1801888482
$83,671.60
in general payments reported to CMS, 2019-2025
78 companies · $17K in 2025
The $17K reported for 2025 was more than what 86% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,085 · 2020: $338 · 2021: $13K · 2022: $10K · 2023: $15K · 2024: $26K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Consulting Fee: $8,990 · Food and Beverage: $7,197 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,725 · Travel and Lodging: $955 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39,879.50 |
| Consulting Fee | $8,989.75 |
| Food and Beverage | $7,197.01 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,725.00 |
| Travel and Lodging | $955.48 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $41,958.34 | 2022-2025 | Ojjaara, Blenrep, Shingrix |
| Daiichi Sankyo INC. | $8,913.45 | 2021-2025 | Enhertu, Injectafer, Vanflyta |
| Astellas Pharma US INC | $6,658.29 | 2020-2024 | Xtandi, Padcev |
| Novartis Pharmaceuticals Corporation | $4,112.34 | 2019-2025 | Promacta |
| Genzyme Corporation | $3,374.75 | 2021-2025 | |
| Tg Therapeutics, INC. | $2,025.00 | 2021 | |
| Cti Biopharma Corp. | $1,866.57 | 2022-2023 | Vonjo |
| Janssen Scientific Affairs, LLC | $1,645.81 | 2022-2025 | Erleada, Pipeline, Akeega |
| Karyopharm Therapeutics INC. | $1,622.74 | 2020-2023 | Xpovio |
| Seagen INC. | $1,262.00 | 2022-2023 | |
| Geron Corporation | $1,251.06 | 2025 | Rytelo |
| Incyte Corporation | $1,096.06 | 2019-2024 | Jakafi, Monjuvi, Pemazyre |
| Astrazeneca Pharmaceuticals LP | $1,039.54 | 2021-2025 | Imfinzi, Enhertu |
| Emd Serono, INC. | $666.67 | 2020-2024 | Bavencio |
| E.R. Squibb & Sons, L.L.C. | $600.36 | 2019-2025 | Opdivo, Opdualag, Krazati |
Show all 78 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $548.09 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $436.62 | 2019-2025 | Keytruda, Welireg, Reblozyl |
| Gilead Sciences, INC. | $340.12 | 2021-2025 | Trodelvy |
| Celgene Corporation | $264.31 | 2021-2025 | Reblozyl, Pomalyst, Opdivo |
| Kite Pharma, INC. | $251.46 | 2019-2025 | Yescarta |
| Janssen Biotech, INC. | $234.93 | 2019-2025 | Tecvayli, Darzalex, Erleada |
| Abbvie INC. | $230.40 | 2024-2025 | |
| Amgen INC. | $226.57 | 2019-2023 | Lumakras, Blincyto, Kyprolis |
| Pharmacyclics LLC, An Abbvie Company | $212.69 | 2020-2023 | Imbruvica, Epkinly |
| Agios Pharmaceuticals, INC. | $180.73 | 2024-2025 | Pyrukynd |
| Beigene USA, INC. | $180.49 | 2021-2024 | Brukinsa, Tevimbra |
| Alexion Pharmaceuticals, INC. | $150.14 | 2024-2025 | Soliris, Ultomiris |
| Genentech USA, INC. | $140.44 | 2023-2025 | Lunsumio, Polivy, Phesgo |
| Bayer Healthcare Pharmaceuticals INC. | $129.80 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $122.42 | 2019-2022 | |
| Octapharma USA, INC. | $118.59 | 2023-2025 | Octagam Immune Globulin (Human), Panzyga |
| Takeda Pharmaceuticals U.S.A., INC. | $98.66 | 2021-2024 | Iclusig, Fruzaqla, Alunbrig |
| Adaptive Biotechnologies Corporation | $96.22 | 2025 | Clonoseq |
| Springworks Therapeutics, INC. | $90.28 | 2024-2025 | Ogsiveo |
| Lilly USA, LLC | $89.84 | 2022-2024 | Retevmo, Verzenio, Jaypirca |
| Myriad Genetic Laboratories, INC. | $89.25 | 2023-2024 | Myrisk |
| Aveo Pharmaceuticals, INC. | $82.73 | 2023-2025 | Fotivda |
| Tersera Therapeutics LLC | $75.51 | 2024 | Zoladex, Quzyttir |
| Exelixis INC. | $71.52 | 2022-2025 | Cabometyx |
| Stemline Therapeutics INC. | $68.46 | 2024 | Elzonris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.35 | 2019-2024 | Gilotrif |
| Array Biopharma INC | $56.79 | 2019-2025 | Lorbrena, Braftovi, Mektovi |
| Eisai INC. | $51.96 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $50.99 | 2023 | Zepzelca |
| Cardinal Health 110 LLC | $48.82 | 2024 | |
| Tempus Ai, INC | $44.86 | 2024-2025 | Xt Cdx |
| Morphosys, US INC. | $34.61 | 2023-2024 | Monjuvi |
| Heron Therapeutics, INC. | $34.10 | 2020-2023 | Cinvanti |
| Accord Healthcare, INC. | $33.88 | 2025 | |
| G1 Therapeutics, INC. | $33.84 | 2023 | Cosela |
| Servier Pharmaceuticals LLC | $33.41 | 2021-2024 | |
| Adc Therapeutics America, INC. | $32.56 | 2024-2025 | |
| Foundation Medicine, INC. | $32.50 | 2019 | |
| Sobi, INC | $30.60 | 2025 | |
| Puma Biotechnology, INC. | $27.32 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $26.11 | 2023 | Libtayo |
| Pharmacosmos Therapeutics INC. | $25.71 | 2025 | Monoferric |
| Caris Mpi, INC. | $24.52 | 2025 | Mi Cancer Seek |
| Clovis Oncology, INC. | $24.00 | 2019 | |
| Mirati Therapeutics, INC. | $23.98 | 2023 | Krazati |
| Dova Pharmaceuticals | $23.69 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $22.13 | 2023 | Valchlor |
| Aadi Bioscience, INC. | $21.52 | 2022 | |
| Spectrum Pharmaceuticals INC. | $21.06 | 2023 | Rolvedon |
| Alnylam Pharmaceuticals INC. | $20.45 | 2022 | |
| Sandoz INC. | $19.06 | 2024 | Cyclophosphamide |
| Sumitomo Pharma America, INC. | $17.12 | 2025 | Orgovyx |
| Taiho Oncology, INC. | $17.06 | 2023 | |
| Iovance Biotherapeutics, INC. | $16.80 | 2025 | Amtagvi |
| Deciphera Pharmaceuticals INC. | $16.74 | 2024 | Qinlock |
| Kyowa Kirin, INC. | $15.91 | 2023 | Poteligeo |
| Ipsen Biopharmaceuticals, INC | $15.80 | 2023 | Tazverik |
| Sirtex Medical INC | $15.79 | 2024 | Sir-Spheres Microspheres |
| Pharming Healthcare, INC. | $14.52 | 2023 | Ruconest |
| Lexicon Pharmaceuticals, INC. | $14.36 | 2019 | |
| Genmab U.S., INC. | $13.84 | 2024 | Tivdak |
| Sun Pharmaceutical Industries INC. | $13.68 | 2023 | Odomzo, Yonsa |
| Eusa Pharma (US) LLC | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Marinella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.